Reuters columnist says Syngenta IPO pricing puts too big a premium on it
A Reuters columnist argues Syngenta's targeted $66 bln valuation would give it a bigger premium to rivals like Corteva than its pipeline deserves.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
The seeds and crop-protection group is aiming for a market value of at least $66 bln, which a Reuters columnist says implies its enterprise value including debt has doubled in less than nine years under Chinese ownership. Per Reuters, advisers UBS and China International Capital are marketing the shares at 15 to 20 times expected 2026 core earnings.
For the first nine months of the year, Syngenta reported EBITDA of $3.2 bln, up 1%. Its EBITDA margin rose 100 basis points to 18.4% while sales fell 5%. Net debt stood at $24.8 bln at the end of 2024.
why it matters
The IPO valuation sets a reference point for the seeds and crop-protection sector, so investors are likely to compare it with Corteva and other producers.
market impact
Corteva and agrochemical stocks: a rich IPO valuation could reset benchmarks for rivals
tags
instruments
sources
- Syngenta sprinkles too much fertiliser on IPO — Reuters, 2 November 2026 at 02:38 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗